Purpose. The efficacy and safety of i.v. alteplase up to 4.5 hours after acute ischemic stroke (AIS) onset were evaluated. Summary. Stroke is the leading cause of disability in the elderly ...

Recombinant human prourokinase is noninferior to alteplase for acute ischemic stroke outcomes and is associated with decreased rates of symptomatic intracranial hemorrhage and major bleeding ...